Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-08-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
第二届董事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 2nd Board of Directors of Zhejiang Tailin Biotechnology Co., Ltd. It includes approval of the 2020 semi-annual report and a special report on the use of raised funds during the period. The document states that the full semi-annual report and the special report are published on the official disclosure website (cninfo.com.cn) and provides links to those reports. The document itself is short (1252 characters) and does not contain the actual financial statements or detailed report content, but rather announces the board meeting decisions and points to the full reports elsewhere. According to the "Menu vs Meal" rule, this is an announcement of the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement of board resolutions and report approvals without the full report content.
2020-08-27 Chinese
关于2020年半年度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (348 characters) stating that the company's 2020 semi-annual report has been disclosed on the official information disclosure website. It does not contain the actual semi-annual report or substantive financial data, but rather directs investors to where the report can be found. This fits the criteria for a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2020-08-27 Chinese
安信证券股份有限公司关于公司持续督导期间2020年半年报跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导期间 2020 年半年报跟踪报告" which translates to "Continuous Supervision Period 2020 Semi-Annual Report Tracking Report". It is issued by a sponsoring institution (安信证券股份有限公司) regarding the company 浙江泰林生物技术股份有限公司. The content includes oversight activities, review of company disclosures, governance supervision, and compliance with commitments related to the 2020 semi-annual report. The document is a follow-up or tracking report on the half-year report rather than the half-year report itself. It does not contain actual financial statements or substantive financial data but rather supervisory and compliance information related to the interim report period. The document length is 2516 characters, which is relatively short and consistent with a monitoring or tracking report rather than a full interim report. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a regulatory compliance and supervision report related to the interim report period.
2020-08-27 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '浙江泰林生物技术股份有限公司 2020 年半年度报告全文', which translates to 'Zhejiang Tailin Bioengineering Co., Ltd. 2020 Semi-Annual Report Full Text'. It explicitly states it is a '半年度报告' (half-year report) for the period January to June 2020. The content includes detailed financial data, company business overview, management discussion, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
董事会关于2020年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Zhejiang Tailin Biotechnology Co., Ltd. board regarding the storage and usage of funds raised in the first half of 2020. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange about the management and use of raised funds. The report includes specifics on the amount raised, timing, usage, balance, and compliance with relevant laws and regulations. It also includes tables and attachments detailing the use of funds, investment projects, and approvals from board meetings and shareholders. The document is not a general financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a specialized report focused on the management and use of capital raised through equity issuance, which fits the definition of a Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive financial and operational details about fundraising and fund usage, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2020-08-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding a change in accounting policies due to new accounting standards issued by the Ministry of Finance of the People's Republic of China. It explains the nature of the accounting policy change, the effective date, and the impact on the company. The document is short (930 characters) and serves as a formal disclosure of the accounting policy change rather than a full financial report or audit report. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2020-08-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.